IMA Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

IMA Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$169	Hold	1	–	–	﹤0.01%	1349
2026 Q1	$131	Hold	1	–	–	﹤0.01%	992
2025 Q4	$141	Hold	1	–	–	﹤0.01%	979
2025 Q3	$140	Hold	1	–	–	﹤0.01%	535
2025 Q2	$126	Buy	+1	New	+$115	﹤0.01%	543

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IMA Advisory Services's NBIX Position: Q2 2026 in Review

IMA Advisory Services held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 1 share worth $169. The position accounts for ﹤0.01% of the portfolio, ranked #1349.

IMA Advisory Services first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

IMA Advisory Services held 1 share of Neurocrine Biosciences worth $169 as of Q2 2026.
IMA Advisory Services left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of IMA Advisory Services's portfolio in Q2 2026, its #1349 holding.
IMA Advisory Services first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on IMA Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.